Cellectis (LTS:0WA2) Asset Impairment Charge : €0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Cellectis Asset Impairment Charge?

Cellectis's Asset Impairment Charge for the three months ended in Mar. 2025 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.

Cellectis Asset Impairment Charge Historical Data

The historical data trend for Cellectis's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Asset Impairment Charge Chart

Cellectis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

Cellectis Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Cellectis Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Cellectis Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Cellectis's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

CLLS:USA ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines